Neuroendocrine Response to Oral Alcohol Administration

Status Completed

Clinical Trial Summary

This study proposes to examine both the peripheral and central nervous system responses when light social drinkers and binge/heavy social drinkers are exposed to oral ethanol. The findings will provide a greater understanding of the brain mechanisms (cerebral blood flow and functional connectivity) underlying the association between stress, cortisol release, heart rate variability, alcohol craving, and alcohol stimulant and sedative effects. This knowledge could be significant in developing new therapies for the treatment of alcoholism.

Clinical Trial Description

This study was a single-blind, mixed Between Subjects and repeated measures across Alcohol and Placebo conditions in separate sessions in a 2 scan neuroimaging experiment. The two groups of participants were Moderate Social Drinkers and Binge/Heavy Social Drinkers, categorized on the basis of NIAA criteria for moderate non-binge and binge/heavy drinking. Subjects were randomly assigned to receive alcoholic or non-alcoholic beer in scanning condition 1 or condition 2. Before each scan, they were exposed to 3 12 Oz. alcoholic beer or 3 12 Oz. non-alcoholic beer via an Alcohol Taste Test (ATT) during which they were asked to taste the beers to determine if they were same or different. The order of the two conditions was counterbalanced and randomized across participants. Cerebral blood flow (CBF) was then measured using Arterial Spin Labeling. In addition to measuring the different effects of alcoholic beer vs. non-alcoholic beer on CBF, the investigators also measured subjective alcohol effects, alcohol craving, breath alcohol levels, cortisol, and ACTH. Statistical tests were performed to determine if these dependent measures were due to Group, Condition, or a Group x Condition interaction. Finally, the relationship between these variables and the amount of beer consumed at the second post-scan ATT was examined. The post-scan ATT only presented with the choice to drink non-alcoholic beer in order to more clearly predict behavioral motivation for alcohol from PreATT alcohol response in cortisol, CBF and subjective ratings. Data was obtained by research staff, nurse, and MRI technician who were blind to condition as were the subjects but PI and project director were not blind. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03165942
Study type	Interventional
Source	Yale University
Contact
Status	Completed
Phase	Phase 1
Start date	September 8, 2016
Completion date	June 30, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05343039` - Technology Enhanced Adolescent Mental Health (TEAM)	N/A
Active, not recruiting	`NCT04070521` - EEG Monitoring in the Emergency Department
Completed	`NCT03169244` - Buproprion for Binge Drinking	Phase 2
Completed	`NCT05036499` - PFI for Pain-Related Anxiety Among Hazardous Drinkers With Chronic Pain	N/A
Recruiting	`NCT04368416` - Anxiety/Depression, Sleep and Alcohol in Elderly Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints
Not yet recruiting	`NCT04557631` - Evaluation of the Threshold for the Interpretation of the Results of a Method for the Blood Determination of Phosphatidyléthanol
Terminated	`NCT00890149` - Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults	Phase 2
Completed	`NCT02179749` - Mifepristone Treatment of Alcohol Use Disorder	Phase 2
Completed	`NCT02448134` - A Community-Based Strategy for Preventing Underage Drinking	N/A
Completed	`NCT02681406` - Smartphone Based Continuing Care for Alcohol	N/A
Withdrawn	`NCT01847300` - cSBI-M for Young Military Personnel	N/A
Withdrawn	`NCT01796158` - Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use	N/A
Completed	`NCT01553136` - Varenicline Treatment of Alcohol Dependence in Smokers	Phase 2
Withdrawn	`NCT01511679` - Brain-imaging and Adolescent Neuroscience Consortium	N/A
Terminated	`NCT01408641` - Topiramate for Alcohol Use in Posttraumatic Stress Disorder	N/A
Withdrawn	`NCT01275391` - cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use	Phase 1/Phase 2
Active, not recruiting	`NCT01539525` - Screening to Augment Referral to Treatment- Project START	Phase 2
Completed	`NCT01207258` - Brief Intervention for Problem Drinking and Partner Violence	Phase 2
Completed	`NCT00907309` - Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use	Phase 1/Phase 2
Completed	`NCT01518972` - Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.